Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Line item | Aversi-Pharma | GEPHA | Georgia Pharmacy Group | PSP Pharma | Impexpharm |
|---|---|---|---|---|---|
| Total Revenue | 980,306 | 861,800 | 861,800 | 845,163 | 110,181 |
| Total COGS | -628,105 | -588,554 | -588,554 | -655,105 | -77,287 |
| Gross Profit | 352,201 | 273,246 | 273,246 | 190,058 | 32,894 |
| Gross Margin | 35.9% | 31.7% | 31.7% | 22.5% | 29.9% |
| Other Operating Income | 4,972 | 4,409 | 4,480 | — | — |
| Total Operating Expenses | -246,898 | -155,294 | -161,293 | -132,946 | -25,933 |
| EBITDA | 110,275 | 122,361 | 116,433 | 57,112 | 6,960 |
| EBITDA Margin | 11.2% | 14.2% | 13.5% | 6.8% | 6.3% |
| Total D&A | -44,917 | -41,767 | -41,911 | -20,234 | -5,045 |
| EBIT / Operating Income | 65,358 | 80,594 | 74,522 | 36,878 | 1,915 |
| Total Interest Income | 5,412 | 533 | 2,413 | 6,310 | 438 |
| Total Interest Expense | -5,815 | -15,098 | -34,970 | -12,159 | -1,714 |
| Total Other Income | -1,771 | -13,979 | -14,527 | 79 | 2,744 |
| Profit Before Tax | 63,184 | 52,050 | 27,438 | 31,108 | 3,384 |
| Total Income Tax | 0 | -231 | -231 | 0 | -20 |
| Net Profit / (Loss) | 63,184 | 51,819 | 27,141 | 28,984 | 2,894 |
| Net Margin | 6.4% | 6.0% | 3.1% | 3.4% | 2.6% |
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| GEPHA | Pharma | 14.2% | 49th pct | 110 |
| Georgia Pharmacy Group | Pharma | 13.5% | 46th pct | 110 |
| Aversi-Pharma | Pharma | 11.2% | 43rd pct | 110 |
| PSP Pharma | Pharma | 6.8% | 30th pct | 110 |
| Impexpharm | Pharma | 6.3% | 26th pct | 110 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.